

## CHAMPVA POLICY MANUAL

**CHAPTER:** 2  
**SECTION:** 17.22  
**TITLE:** TAP WATER IONTOPHORESIS DEVICES

---

---

**AUTHORITY:** 38 USC 1713; 38 CFR 17.270(a) and 17.272(a)

**RELATED AUTHORITY:** 32 CFR 199.4(d)(3)(ii)

**TRICARE POLICY MANUAL:** Chapter 7, Section 3.15

---

---

### I. EFFECTIVE DATE

May 18, 1994

### II. DESCRIPTION

A tap water device using iontophoresis to administer tap water for the treatment of hyperhidrosis (excessive perspiration due to over activity of sweat glands). Treatment consists of passing a direct current to significant magnitude and duration into the skin to obstruct the sweat glands. The current is delivered to the skin while the hands or feet are immersed in a pair of pans, each of which has an electrode which also is in the water.

### III. POLICY

A. Medically necessary and appropriate use of tap water iontophoresis devices approved by the Food and Drug Administration (FDA) for the purpose of treating hyperhidrosis may be cost-shared by CHAMPVA.

B. The following devices have FDA approval as durable medical equipment for use in the treatment of hyperhidrosis through iontophorese:

1. Drionic Iontophoresis device; and
2. R.A. Fischer Galvanic Generator models 2800 and 2900.

**\*END OF POLICY\***